.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,846,413

« Back to Dashboard
Patent 6,846,413 protects STRIVERDI RESPIMAT, SPIRIVA RESPIMAT, COMBIVENT RESPIMAT, and STIOLTO RESPIMAT, and is included in four NDAs.

This patent has fifty-one patent family members in thirty-five countries.

Summary for Patent: 6,846,413

Title: Microstructured filter
Abstract:A microstructured filter for a fluid, the filter having an inlet for unfiltered fluid and an outlet for filtered fluid, the filter comprising: a plurality of projections (7) which are arranged in at least two rows (3) in mutually juxtaposed relationship and which project out of a base plate (1) and which are an integral component of the base plate, a plurality of passages (8) between the projections (7), and a cover plate which is securable to the base plate to cover the projections (7) and the passages (8), wherein the passages form a plurality of through paths from the inlet to the outlet, said inlet comprises an elongate inlet slot (5) for the unfiltered fluid, which extends over approximately the entire filter width and which is approximately as high as the projection (7) projecting out of the base plate, on the outlet side of the filter. The filter according to the invention remains operational, even if a part of the filter area is obstructed. The filter is used for example in an atomizer with which an aerosol is produced from a fluid which contains a medicament.
Inventor(s): Kadel; Klaus (Willen, DE), Geser; Johannes (Dortmund, DE), Eicher; Joachin (Dortmund, DE), Freund; Bernhard (Gau-Algesheim, DE), Dunne; Stephen Terence (Woodbridge, DE), Bachtler; Wulf (Mainz, DE)
Assignee: Boehringer Ingelheim International GmbH (DE)
Application Number:09/509,201
Patent Claim Types:
see list of patent claims
Device;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 66th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYes6,846,413► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXNo6,846,413► subscribeY
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYes6,846,413► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,846,413

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 42 439Sep 26, 1997
PCT Information
PCT FiledAugust 28, 1998PCT Application Number:PCT/GB98/02604
PCT Publication Date:April 08, 1999PCT Publication Number: WO99/16530

Non-Orange Book Patents for Patent: 6,846,413

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,645,383Microstructured filter► subscribe
6,977,042 Microstructured filter► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,846,413

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina010946► subscribe
Austria228386► subscribe
Austria357956► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc